Joseph R Bertino
Overview
Explore the profile of Joseph R Bertino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rather G, Pramono A, Szekely Z, Bertino J, Tedeschi P
Pharmacol Ther
. 2021 Apr;
226:107864.
PMID: 33894275
Cancer cells require increased levels of NADPH for increased nucleotide synthesis and for protection from ROS. Recent studies show that increased NADPH is generated in several ways. Activated AKT phosphorylates...
2.
Rather G, Anyanwu M, Minko T, Garbuzenko O, Szekely Z, Bertino J
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33652640
Background: We tested the antitumor effects of a modified E2F peptide substituting D-Arg for L-Arg, conjugated to penetratin (PEP) against solid tumor cell lines and the CCRF-leukemia cell line, alone...
3.
Pramono A, Rather G, Herman H, Lestari K, Bertino J
Biomolecules
. 2020 Mar;
10(3).
PMID: 32111066
Actively proliferating cancer cells require sufficient amount of NADH and NADPH for biogenesis and to protect cells from the detrimental effect of reactive oxygen species. As both normal and cancer...
4.
Lin Z, Lin S, Xie P, Lin C, Rather G, Bertino J, et al.
Sci Rep
. 2020 Feb;
10(1):3015.
PMID: 32080205
The rapid qualitative assessment of surface markers on cancer cells can allow for point-of-care prediction of patient response to various cancer drugs. Preclinical studies targeting cells with an antibody to...
5.
Ahuja K, Rather G, Lin Z, Sui J, Xie P, Le T, et al.
Microsyst Nanoeng
. 2019 Oct;
5:34.
PMID: 31645995
We present a novel method to rapidly assess drug efficacy in targeted cancer therapy, where antineoplastic agents are conjugated to antibodies targeting surface markers on tumor cells. We have fabricated...
6.
Mehnert J, Kaveney A, Malhotra J, Spencer K, Portal D, Goodin S, et al.
Cancer Chemother Pharmacol
. 2019 Aug;
84(4):899-907.
PMID: 31463691
Purpose: Given the evidence that coordinate inhibition of AKT induces autophagy, we studied the combination of the AKT inhibitor, MK-2206 with hydroxychloroquine (HCQ) in patients with advanced solid tumors. Methods:...
7.
Stein M, Malhotra J, Tarapore R, Malhotra U, Silk A, Chan N, et al.
J Immunother Cancer
. 2019 May;
7(1):136.
PMID: 31118108
Background: ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human...
8.
Rather G, Lin S, Lin H, Szekely Z, Bertino J
Front Oncol
. 2019 Apr;
9:258.
PMID: 31024856
Matriptase is a transmembrane serine protease, synthesized as an inactive single-chain zymogen on the endoplasmic reticulum and transported to the plasma membrane. Matriptase is activated in different epithelial and some...
9.
Goldfinger M, Xu M, Bertino J, Cooper D
Clin Lymphoma Myeloma Leuk
. 2019 Mar;
19(6):e307-e311.
PMID: 30926391
Lenalidomide has modest single-agent activity comparable with other newer drugs in recurrent diffuse large B cell lymphoma with response rates between 19% and 28%. Retrospective series and 1 prospective study...
10.
Chaturvedi S, Bertino J
Methods Mol Biol
. 2019 Feb;
1866:1-12.
PMID: 30725403
Cancer cells require exogenous methionine for survival and therefore methionine restriction is a promising avenue for treatment. The basis for methionine dependence in cancer cells is still not entirely clear....